Brought to you by 
J&J's Janssen, Tibotec sign drug discovery deal with ChemDiv
12 Jan 2016
Executive Summary
CRO ChemDiv Inc. has agreed to use its drug discovery technologies to identify small-molecules against targets of interest to Johnson & Johnson’s Janssen Pharmaceutica NV and Tibotec Pharmaceuticals Ltd. (infectious disease therapeutics) divisions. The deal covers multiple projects.
Deal Industry
- Contract Research Organization-CRO
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- Molecular Diversity
-
Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J's Janssen, Tibotec sign drug discovery deal with ChemDiv
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice